WO44977 Resistance to Breast Cancer Therapy Study

• Research type

  Research Study

• Full title

  A MULTI COHORT TRANSLATIONAL RESEARCH STUDY TO INVESTIGATE MECHANISMS OF RESISTANCE TO BREAST CANCER THERAPIES

• IRAS ID

  336973

• Contact name

  Laura Kenny

• Contact email

  l.kenny@imperial.ac.uk

• Sponsor organisation

  Roche Products Limited

• Duration of Study in the UK

  3 years, 11 months, 23 days

• Research summary

  REMERGE is a scientific research study that does not use any treatment or new drug but patients will be asked to donate tumour biopsy samples and blood samples.
  The purpose of this study is to assess and understand the changes that happen to breast cancer over time, with the intention to improve breast cancer therapies or develop new therapies in the future. The data from this trial will help to better understand the biology of breast cancer, which may explain the reasons for the uncontrolled growth of the cancer cells and why these are not responding well to
  some treatments.
  The REMERGE study is designed for participants diagnosed with breast cancer who are being treated with an anti-cancer therapy.
  Breast cancer patients will be asked to provide consent to donate tumor tissue and blood samples for testing if their disease starts to worsen. This study requires the participant to attend the clinic for one visit in person to collect samples of their tumor tissue and a small volume of blood. Total time of participation in the clinical trial will be about 2-3 weeks including time for follow up.
  The main clinical trial endpoint (the main results measured in the trial) is to find out how tumors change during treatment for breast cancer in order to understand why anti-cancer therapies stop working.
  Participants can take part in this trial if they have breast cancer, if they received anti-cancer therapy and the disease starts to worsen, and if they provide consent to donate their tissue and blood samples.
  There are no direct benefits from donating the samples. However, research performed on these samples may help other people with similar medical conditions in the future.
  A Total of 320 patients will be recruited globally, 61 in the UK

• REC name

  West Midlands - Solihull Research Ethics Committee

• REC reference

  24/WM/0010

• Date of REC Opinion

  15 Jan 2024

• REC opinion

  Favourable Opinion